Table 1.
Demographic and Clinical Characteristics at Baseline
| Minors N=149 | Adults N=723 | Total (Minors and Adults) N=872 | ||||
|---|---|---|---|---|---|---|
| <3 AC | ≥3 AC | <3 AC | ≥3 AC | <3 AC | ≥3 AC | |
| N (%) | 105 (70.5) | 44 (29.5) | 684 (94.6) | 39 (5.4) | 789 (90.5) | 83 (9.5) |
| Sex, n (%) | ||||||
| Male | 59 (56.2) | 35 (79.5) | 273 (39.9) | 10 (25.6) | 332 (42.1) | 45 (54.2) |
| Female | 46 (43.8) | 9 (20.5) | 411 (60.1) | 29 (74.4) | 457 (57.9) | 38 (45.8) |
| Age at omalizumab initiation, years | ||||||
| Mean±SD | 11.5±3.12 | 11.3±2.97 | 51.4±13.96 | 39.3±14.19 | 46.1±18.82 | 24.5±17.20 |
| Allergic Comorbidities, n (%) | ||||||
| Yes | 90 (85.7) | 44 (100.0) | 360 (52.6) | 39 (100.0) | 450 (57.0) | 83 (100.0) |
| Perennial rhinitis | 67 (74.4) | 41 (93.2) | 263 (73.1) | 37 (94.9) | 330 (73.3) | 78 (94.0) |
| Seasonal rhinitis | 25 (27.8) | 30 (68.2) | 82 (22.8) | 24 (61.5) | 107 (23.8) | 54 (65.1) |
| Conjunctivitis | 11 (12.2) | 20 (45.5) | 49 (13.6) | 36 (92.3) | 60 (13.3) | 56 (67.5) |
| Atopic dermatitis | 17 (18.9) | 33 (75.0) | 23 (6.4) | 17 (43.6) | 40 (8.9) | 50 (60.2) |
| Food allergy | 9 (10.0) | 28 (63.6) | 24 (6.7) | 16 (41.0) | 33 (7.3) | 44 (53.0) |
| Number of exacerbations† | ||||||
| n | 105 | 44 | 684 | 39 | 789 | 83 |
| Mean±SD | 5.2±4.03 | 5.2±3.51 | 4.3±3.08 | 4.2±2.74 | 4.5±3.24 | 4.7±3.19 |
| Number of hospitalisations† | ||||||
| n | 58 | 21 | 281 | 14 | 339 | 35 |
| Mean±SD | 2.3±1.87 | 2.1±2.17 | 1.7±1.39 | 1.6±0.85 | 1.8±1.50 | 1.9±1.77 |
| Total serum IgE, IU/mL | ||||||
| n | 104 | 44 | 645 | 38 | 749 | 82 |
| Mean±SD | 1198.8±1412.85 | 1744.2±1445.2 | 512.5±752.00 | 801.7±1351.82 | 607.8±904.52 | 1307.4±1472.11 |
| Blood eosinophil count†, cells/µL | ||||||
| n | 105 | 44 | 684 | 39 | 789 | 83 |
| Mean±SD | 667.1±525.87 | 726.4±464.02 | 457.5±614.34 | 328.3±224.44 | 485.4±607.20 | 593.3±419.76 |
Note: †One year before omalizumab initiation.
Abbreviations: AC, allergic comorbidities; Ig, immunoglobulin; SD, standard deviation.